New hope for tough blood cancers: first test of promising pill begins

NCT ID NCT04883957

Summary

This is an early-stage study to find a safe dose of a new oral drug called BGB-11417 for adults with advanced B-cell cancers that have come back or stopped responding to standard treatments. The main goals are to check the drug's safety, see how the body processes it, and look for early signs that it might shrink tumors. The study will enroll about 64 people with specific types of lymphoma or leukemia.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MATURE B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, 200032, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University Peoples Hospital

    Beijing, Beijing Municipality, 100044, China

  • Shenzhen Peoples Hospital

    Shenzhen, Guangdong, 518020, China

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

Conditions

Explore the condition pages connected to this study.